Image via Wikipedia
AUGUSTA, Ga. – Medical College of Georgia researchers are conducting the first FDA-approved clinical trial to determine whether an infusion of stem cells from umbilical cord blood can improve the quality of life for children with cerebral palsy.
The study will include 40 children age 2-12 whose parents have stored cord blood at the Cord Blood Registry in Tucson, Ariz.
Umbilical cord blood is rich in stem cells, which can divide and morph into different types of cells throughout the body, said Dr. James Carroll, professor and chief of pediatric neurology in MCG School of Medicine and principal investigator
The Ospedali Riuniti of Bergamo is the top center for the collection of umbilical cord blood in the Lombardy region, said the hospital, which received an award at the Policlinico di Milano (where the umbilical cord blood bank is located) for the second consecutive year for its commitment and professionalism with which it carries out its work, providing an important source of stem cells.
“Our collection program started in 2004,” explained Bruna Pasini, the head obstetrician, also in charge of the collection of umbilical cord blood for the hospital. “At that time we started to collaborate with the Milano
Vanderbilt-Ingram Cancer Center performs around 215 stem cell and bone marrow transplants each year, providing care leading up
Cord Blood Registry (CBR) is the exclusive partner for a growing number of clinical researchers focusing on the use of a child’s own cord blood stem cells to help treat pediatric brain injury and acquired hearing loss. To ensure consistency in cord blood stem cell processing, storage and release for infusion, three separate trials have included CBR in their FDA-authorized protocol—including two at the University of Texas Health Science Center at Houston (UTHealth) working in partnership with Children’s Memorial Hermann Hospital, and a third at Georgia Health Sciences University, home of the Medical College of Georgia (MCG). This makes
(…) Since 2006, according to NECBB records, the number of banked units used in transplants has doubled. The company attributes this increase in cord blood usage to the ever evolving research surrounding cord blood stem cells.
“We have always reminded parents that stem cell therapies are advancing very quickly and it is difficult to know what the possibilities are. The fact that more parents are using cells they stored suggests that the scope of treatments available is encouraging,” said Dr. David Matzilevich, Chief Scientific Officer of NECBB. “We are confident that the cells found in cord blood are extremely valuable